Floatz logo

Pyrotinib

Small Cell Lung Cancer

BeOne MedicinesSmall moleculePhase 4 / ApprovedActive
BB
66/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
67/ 100
Competitive Position
65/ 100

Competitive context

108 Active assets in the Small Cell Lung Cancer cohort.

Asset / SponsorPhaseRating
Hycamtin
AbbVie
Phase 4BB
Irinotecan
Sichuan University
Phase 4BB
ETOPOSIDE
Sichuan University
Phase 4BB
Carboplatin
University of Maryland, Baltimore
Phase 4BB
CIS-DIAMMINEDICHLOROPLATINUM II
National Cancer Institute (NCI)
Phase 4BB

View all 50 →

Same molecule, other indications

Pyrotinib is also rated in:

Non Small Cell Lung CancerDormant
BB
Indicative ·
70 / 100
View asset →
breast carcinomaDormant
BB
Indicative ·
70 / 100
View asset →
HER2 positive breast carcinomaDormant
BB
Indicative ·
66 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →